Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR1B | P28222 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR1E | P28566 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27798621 | 1.00 | TACR1 (0.61) | TACR1KDM4EMAPTMEN1LMNA | |
| SCHEMBL28537587 | 1.00 | TACR1 (0.61) | TACR1KDM4EMAPTMEN1LMNA | |
| SCHEMBL1720664 | 1.00 | TACR1 (0.61) | TACR1KDM4EMAPTMEN1LMNA | |
| SCHEMBL1720662 | 1.00 | TACR1 (0.61) | TACR1KDM4EMAPTMEN1LMNA | |
| SCHEMBL6240398 | 1.00 | TACR1 (0.61) | TACR1KDM4EMAPTMEN1LMNA | |
| SCHEMBL6243067 | 1.00 | TACR1 (0.61) | TACR1KDM4EMAPTMEN1LMNA | |
| SCHEMBL16278133 | 1.00 | TACR1 (0.61) | TACR1KDM4EMAPTMEN1LMNA | |
| SCHEMBL6240394 | 1.00 | TACR1 (0.61) | TACR1KDM4EMAPTMEN1LMNA | |
| SCHEMBL12966390 | 1.00 | TACR1 (0.61) | TACR1KDM4EMAPTMEN1LMNA | |
| SCHEMBL6244860 | 1.00 | TACR1 (0.61) | TACR1KDM4EMAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1113795-B1 | TRYPTOPHANYL ESTERS AND THEIR N-ACYL DERIVATIVES FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED OR EXACERBATED BY OXIDATION PROCESSES | MAX PLANCK GESELLSCHAFT (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040176436-A1 | Tryptophanyl-esters and their N-acyl derivatives for preventing and treating diseases caused or aggravated by oxidation processes | BEHL CHRISTIAN (DE) | 2004-09-09 | — | — | US | claimed |
| US-20010014695-A1 | Tryptophanyl-esters and their n-acyl derivatives for preventing and treating diseases caused or aggravated by oxidation processes | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2001-08-16 | — | — | US | claimed |
| EP-1113795-A2 | TRYPTOPHANYL ESTER AND THEIR N-ACYL DERIVATIVES FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED OR EXACERBATED BY OXIDATION PROCESSES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2001-07-11 | — | — | EP | claimed |
| WO-2000015206-A2 | TRYPTOPHANYL ESTER AND THEIR N-ACYL DERIVATIVES FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED OR EXACERBATED BY OXIDATION PROCESSES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2000-03-23 | — | — | WO | claimed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176436-A1 | Tryptophanyl-esters and their N-acyl derivatives for preventing and treating diseases caused or aggravated by oxidation processes | AADAT, KYNU, AADAC | TACR1 4551/4885KDM4E 2274/4885MAPT 521/4885 |
| US-20010014695-A1 | Tryptophanyl-esters and their n-acyl derivatives for preventing and treating diseases caused or aggravated by oxidation processes | AADAT, KYNU, AANAT | TACR1 4354/4885KDM4E 2637/4885MAPT 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.